5 Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. mutational landscape determines sensitivity to PD- 1 blockade in non- small cell lung cancer. Science 2015;348:124–8. 6 Jardim DL, Goodman A, de Melo Gagliato D, et al. The challenges of tumor mutational burden as an Immunotherapy biomarker. Cancer Cell 2021;39:154–73. 7 Fritah H, Rovelli R, Chiang CL- L, et al. The current clinical landscape of personalized cancer vaccines. Cancer Treat Rev 2022;106:S0305- 7372(22)00047- 0.